Novel agents in the management of lung cancer

Current Medicinal Chemistry

Volumn 17, Issue 35, 2010, Pages 4291-4325

  Kennedy, B ^a   Gargoum, F ^a   Bystricky, B ^a   Curran, D R ^a   O'Connor, T M ^a  

^a MERCY UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Growth factors; Lung cancer; New treatments; Tyrosine kinase inhibitors; VEGF

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANERTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; GEFITINIB; GEMCITABINE; GROWTH FACTOR RECEPTOR; INSULIN RECEPTOR; LAPATINIB; MATUZUMAB; NERATINIB; PACLITAXEL; PANITUMUMAB; PELITINIB; PEMETREXED; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; DEHYDRATION; DIARRHEA; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERANCE; DYSPNEA; EPIGLOTTITIS; FATIGUE; FEVER; GASTROINTESTINAL DISEASE; GENE MUTATION; HAND FOOT AND MOUTH DISEASE; HEADACHE; HUMAN; IMMUNOTHERAPY; INTRACELLULAR SIGNALING; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MENINGITIS; MONOTHERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; PROGRESSION FREE SURVIVAL; RASH; SINGLE DRUG DOSE; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS; EPIDERMAL GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; MOLECULAR STRUCTURE; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78650631315     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710793361289     Document Type: Article

References (276)

1. Parkin, D. M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA. Cancer J. Clin., 2005, 55, 74-108.
2. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M. J. Cancer statistics, 2009. CA. Cancer J. Clin., 2009, 59, 225-49.
3. *. ACCP Evidence-Based Clinical Practice Guidelines (2nd ed.). Chest, 2007, 132, 266S-276S.
4. Van der Geer, P.; Hunter, T.; Lindberg, R. A. Receptor proteintyrosine kinases and their signal transduction pathways. Annu. Rev. Cell Biol., 1994, 10, 251-337.
5. Ullrich, A.; Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell, 1990, 61, 203-12.
6. Favoni R. E.; de Cupis, A. The role of polypeptide growth factors in human carcinomas: new targets for a novel pharmacological approach. Pharmacol. Rev., 2000, 52, 179-206.
7. Matsui, Y.; Halter, S. A.; Holt, J. T.; Hogan, B. L.; Coffey, R. J. Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell, 1990, 61, 1147-55.
8. Jhappan, C.; Stahle, C.; Harkins, R. N.; Fausto, N.; Smith, G. H.; Merlino, G. T. TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell, 1990, 61, 1137-46.
9. Salomon, D. S.; Brandt, R.; Ciardiello, F.; Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol., 1995, 19, 183-232.
10. Zandi, R.; Larsen, A. B.; Andersen, P.; Stockhausen, M. T.; Poulsen, H. S. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal., 2007, 19, 2013-23.
11. Yarden, Y. The EGFR family and its ligands in human cancer, signalling mechanisms and therapeutic opportunities. Eur. J. Cancer, 2001, 37, Suppl 4: S3-8.
12. Olayioye, M. A.; Neve, R. M.; Lane, H. A.; Hynes, N. E. The ErbB signalling network: receptor heterodimerization in development and cancer. EMBO J., 2000, 19, 3159-67.
13. Wells, A. EGF receptor. Int. J. Biochem. Cell. Biol., 1999, 31, 637-43.
14. Harris, R. C.; Chung, E.; Coffey, R. J. EGF receptor ligands. Exp. Cell. Res., 2003, 284, 2-13.
15. Watanabe, T.; Shintani, A.; Nakata, M.; Shing, Y.; Folkman, J.; Igarashi, K.; Sasada, R. Recombinant human betacellulin. Molecular structure, biological activities, and receptor interaction. J. Biol. Chem., 1994, 269, 9966-73.
16. Jorissen, R. N.; Walker, F.; Pouliot, N.; Garrett, T. P.; Ward, C. W.; Burgess, A. W. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp. Cell. Res., 2003, 284, 31-53.
17. Harari, P. M. Epidermal growth factor receptor inhibition strategies in oncology. Endocr. Relat. Cancer, 2004, 11, 689-708.
18. Nakamura, H.; Kawasaki, N.; Taguchi, M.; Kabasawa, K. Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. Thorax, 2006, 61, 140-5.
19. Meert, A. P.; Martin, B.; Delmotte, P.; Berghmans, T.; Lafitte, J. J.; Mascaux, C.; Paesmans, M.; Steels, E.; Verdebout, J. M.; Sculier, J. P. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur. Respir. J., 2002, 20, 975-81.
20. Dacic, S.; Flanagan, M.; Cieply, K.; Ramalingam S.; Luketich J.; Belani C.; Yousem, S. A. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am. J. Clin. Pathol., 2006, 125, 860-865.
21. Berghmans, T.; Meert, A. P.; Martin, B.; Ninane, V.; Sculier, J. P. Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer. Eur. Respir. J., 2005, 25, 329-35.
22. Timotheadou, E.; Skarlos, D. V.; Samantas, E.; Papadopoulos, S.; Murray, S.; Skrickova, J.; Christodoulou, C.; Papakostantinou, C.; Pectasides, D.; Papakostas, P.; Kaplanova, J.; Vrettou, E.; Karina, M.; Kosmidis, P.; Fountzilas, G. Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients. Anticancer Res., 2007, 27, 4481-9.
23. Dziadziuszko, R.; Holm, B.; Skov, B. G.; Osterlind, K.; Sellers, M. V.; Franklin, W. A.; Bunn, P. A. Jr.; Varella-Garcia, M.; Hirsch, F. R. Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy. Ann. Oncol., 2007, 18, 447-52.
24. Dazzi, H.; Hasleton, P. S.; Thatcher, N.; Barnes, D. M.; Wilkes, S.; Swindell, R.; Lawson, R. A. Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival. Br. J. Cancer, 1989, 59, 746-9.
25. Jeon, Y. K.; Sung, S. W.; Chung, J. H.; Park, W. S.; Seo, J. W.; Kim, C. W.; Chung, D. H.; Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer, 2006, 54, 387-98.
26. Kim, Y. T.; Kim, T. Y.; Lee, D. S.; Park, S. J.; Park, J. Y.; Seo, S. J.; Choi, H. S.; Kang, H. J.; Hahn, S.; Kang, C. H.; Sung, S. W.; Kim, J. H. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. Lung Cancer, 2008, 59, 111-8.
27. Miyake, M.; Adachi, M.; Huang, C.; Higashiyama, M.; Kodama, K.; Taki, T. A novel molecular staging protocol for non-small cell lung cancer. Oncogene, 1999, 18, 2397-404.
28. Huncharek, M.; Muscat, J.; Geschwind, J. F. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis, 1999, 20, 1507-10.
29. Ciardiello, F.; Tortora, G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res., 2001, 7, 2958-70.
30. Giaccone, G.; Herbst, R. S.; Manegold, C.; Scagliotti, G.; Rosell, R.; Miller, V.; Natale, R. B.; Schiller, J. H.; Von Pawel, J.; Pluzanska, A.; Gatzemeier, U.; Grous, J.; Ochs, J. S.; Averbuch, S. D.; Wolf, M. K.; Rennie, P.; Fandi, A.; Johnson, D. H. Gefitinib in combination with gemcitabine and cisplatin in advanced non-smallcell lung cancer: a phase III trial-INTACT 1. J. Clin. Oncol., 2004, 22, 777-84.
31. Herbst, R. S.; Giaccone, G.; Schiller, J. H.; Natale, R. B.; Miller, V.; Manegold, C.; Scagliotti, G.; Rosell, R.; Oliff, I.; Reeves, J. A.; Wolf, M. K.; Krebs, A. D.; Averbuch, S. D.; Ochs, J. S.; Grous, J.; Fandi, A.; Johnson, D. H. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J. Clin. Oncol., 2004, 22, 785-94.
32. Thatcher, N.; Chang, A.; Parikh, P.; Rodrigues Pereira, J.; Ciuleanu, T.; von Pawel, J.; Thongprasert, S.; Tan, E. H.; Pemberton, K.; Archer, V.; Carroll K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 2005, 366, 1527-37.
33. Chang, A.; Parikh, P.; Thongprasert, S.; Tan, E. H.; Perng, R. P.; Ganzon, D.; Yang, C. H.; Tsao C. J.; Watkins, C.; Botwood, N.; Thatcher, N. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J. Thorac. Oncol., 2006, 1, 847-55.
34. Miller, V. A.; Kris, M. G.; Shah, N.; Patel, J.; Azzoli, C.; Gomez, J.; Krug, L. M.; Pao, W.; Rizvi, N.; Pizzo, B.; Tyson, L.; Venkatraman, E.; Ben-Porat, L.; Memoli, N.; Zakowski, M.; Rusch, V.; Heelan, R. T. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J. Clin. Oncol., 2004, 22, 1103-9.
35. Jänne, P. A.; Gurubhagavatula, S.; Yeap, B. Y.; Lucca, J.; Ostler, P.; Skarin, A. T.; Fidias, P.; Lynch, T. J.; Johnson, B. E. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer, 2004, 44, 221-30.
36. Lynch, T. J.; Bell, D. W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Haserlat, S. M.; Supko, J. G.; Haluska, F. G.; Louis, D. N.; Christiani, D. C.; Settleman, J.; Haber, D. A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to Gefitinib. N. Engl. J. Med., 2004, 350, 2129-39.
37. Paez, J. G.; Jänne, P. A.; Lee, J. C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F. J.; Lindeman, N.; Boggon, T. J.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, M. J.; Sellers, W. R.; Johnson, B. E.; Meyerson, M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497-500.
38. Shigematsu, H.; Lin, L.; Takahashi, T.; Nomura, M.; Suzuki, M.; Wistuba, I. I.; Fong, K. M.; Lee, H.; Toyooka, S.; Shimizu, N.; Fujisawa, T.; Feng, Z.; Roth, J. A.; Herz, J.; Minna, J. D.; Gazdar, A. F. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst., 2005, 97, 339-46.
39. Normanno, N.; De Luca, A.; Bianco, C.; Strizzi, L.; Mancino, M.; Maiello, M. R.; Carotenuto, A.; De Feo, G.; Caponigro, F.; Salomon, D. S. Epidermal growth factor receptor (EGFR) signalling in cancer. Gene, 2006, 366, 2-16.
40. Sordella, R.; Bell, D. W.; Haber, D. A.; Settleman, J. Gefitinibsensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science, 2004, 305, 1163-7.
41. Amann, J.; Kalyankrishna, S.; Massion, P. P.; Ohm, J. E.; Girard, L.; Shigematsu, H.; Peyton, M.; Juroske, D.; Huang, Y.; Stuart Salmon, J.; Kim, Y. H.; Pollack, J. R.; Yanagisawa, K.; Gazdar, A.; Minna, J. D.; Kurie, J. M.; Carbone, D. P. Aberrant epidermal growth factor receptor signalling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res., 2005, 65, 226-35.
42. Tracy, S.; Mukohara, T.; Hansen, M.; Meyerson, M.; Johnson, B. E.; Jänne, P. A. Geftinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res., 2004, 64, 7241-4.
43. Cappuzzo, F.; Magrini, E.; Ceresoli, G. L.; Bartolini, S.; Rossi, E.; Ludovini, V.; Gregorc, V.; Ligorio, C.; Cancellieri, A.; Damiani, S.; Spreafico, A.; Paties, C. T.; Lombardo, L.; Calandri, C.; Bellezza, G.; Tonato, M.; Crinò, L. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J. Natl. Cancer Inst., 2004, 96, 1133-41.
44. Eberhard, D. A.; Johnson, B. E.; Amler, L. C.; Goddard, A. D.; Heldens, S. L.; Herbst, R. S.; Ince W. L.; Jänne, P. A.; Januario, T.; Johnson, D. H.; Klein, P.; Miller, V. A.; Ostland, M. A.; Ramies, D. A.; Sebisanovic, D.; Stinson, J. A.; Zhang, Y. R.; Seshagiri, S.; Hillan, K. J. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol., 2005, 23, 5900-9.
45. Bean, J.; Brennan, C.; Shih, J. Y.; Riely, G.; Viale, A.; Wang, L.; Chitale, D.; Motoi, N.; Szoke, J.; Broderick, S.; Balak, M.; Chang, W. C.; Yu, C. J.; Gazdar, A.; Pass, H.; Rusch, V.; Gerald, W.; Huang, S. F.; Yang, P. C.; Miller, V.; Ladanyi, M.; Yang, C. H.; Pao, W. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. U S A., 2007, 104, 20932-7.
46. Engelman, J. A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J. O.; Lindeman, N.; Gale, C. M.; Zhao, X.; Christensen, J.; Kosaka, T.; Holmes, A. J.; Rogers, A. M.; Cappuzzo, F.; Mok, T.; Lee, C.; Johnson, B. E.; Cantley, L. C.; Jänne, P. A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalling. Science, 2007, 316, 1039-43.
47. Chang, G. C.; Hsu, S. L.; Tsai, J. R.; Liang, F. P.; Lin, S. Y.; Sheu, G. T.; Chen, C. Y. Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells. Biochem. Pharmacol., 2004, 68, 1453-64.
48. Herbst, R. S; Maddox, A. M.; Rothenberg, M. L.; Small, E. J.; Rubin, E. H.; Baselga, J.; Rojo, F.; Hong, W. K.; Swaisland, H.; Averbuch, S. D.; Ochs, J.; LoRusso, P. M. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally welltolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J. Clin. Oncol., 2002, 20, 3815-25.
49. Baselga, J.; Rischin, D.; Ranson, M.; Calvert, H.; Raymond, E.; Kieback, D. G.; Kaye, S. B.; Gianni, L.; Harris, A.; Bjork, T.; Averbuch, S. D.; Feyereislova, A.; Swaisland, H.; Rojo, F.; Albanell, J. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol., 2002, 20, 4292-302.
50. Nakagawa, K.; Tamura, T.; Negoro, S.; Kudoh, S.; Yamamoto, N.; Yamamoto, N.; Takeda, K.; Swaisland, H.; Nakatani, I.; Hirose, M.; Dong, R. P.; Fukuoka, M. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann. Oncol., 2003, 14, 922-30.
51. Ranson, M.; Hammond, L. A.; Ferry, D.; Kris, M.; Tullo, A.; Murray, P. I.; Miller, V.; Averbuch, S.; Ochs, J.; Morris, C.; Feyereislova, A.; Swaisland, H.; Rowinsky, E. K.. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J. Clin. Oncol., 2002, 20, 2240-50.
52. Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J. Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D.; Eek, R.; Horai, T.; Noda, K.; Takata, I.; Smit, E.; Averbuch, S.; Macleod, A.; Feyereislova, A.; Dong, R. P.; Baselga, J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J. Clin. Oncol., 2003, 21, 2237-46.
53. Kris, M. G.; Natale, R. B.; Herbst, R. S. Lynch, T. J. Jr.; Prager, D.; Belani, C. P.; Schiller, J. H.; Kelly, K.; Spiridonidis, H.; Sandler, A.; Albain, K. S.; Cella, D.; Wolf, M. K.; Averbuch, S. D.; Ochs, J. J.; Kay, A. C. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA, 2003, 290, 2149-58.
54. Kim, E. S.; Hirsh, V.; Mok, T.; Socinski, M. A.; Gervais, R.; Wu, Y. L.; Li, L. Y.; Watkins, C. L.; Sellers, M. V.; Lowe, E. S.; Sun, Y.; Liao, M. L.; Osterlind, K.; Reck, M.; Armour, A. A.; Shepherd, F. A.; Lippman, S. M. Douillard, J. Y. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet, 2008, 372, 1809-18.
55. Maruyama, R.; Nishiwaki, Y.; Tamura, T.; Yamamoto, N.; Tsuboi, M.; Nakagawa, K.; Shinkai, T.; Negoro, S.; Imamura, F.; Eguchi, K.; Takeda, K.; Inoue, A.; Tomii, K.; Harada, M.; Masuda, N.; Jiang, H.; Itoh, Y.; Ichinose, Y.; Saijo, N.; Fukuoka, M. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J. Clin. Oncol., 2008, 26, 4244-52.
56. Lee, D. H.; Park, K.; Kim, J. H.; Lee, J. S.; Shin, S. W.; Kang, J. H.; Ahn, M. J.; Ahn, J. S.; Suh, C.; Kim, S. W. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin. Cancer Res., 2010, 16, 1307-14.
57. Nishiwaki, Y.; Yano, S.; Tamura, T.; Nakagawa, K.; Kudoh, S.; Horai, T.; Noda, K.; Takata, I.; Watanabe, K.; Saka, H.; Takeda, K.; Imamura, F.; Matsui, K.; Katakami, N.; Yokoyama, A.; Sawa, Y.; Takada, M.; Kiura, K.; Sugiura, T.; Fukuoka, M.; Uchida, H. [Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib] Gan To Kagaku Ryoho, 2004, 31, 567-73.
58. Mok, T. S.; Wu, Y. L.; Thongprasert, S.; Yang, C. H.; Chu, D. T.; Saijo, N.; Sunpaweravong, P.; Han, B.; Margono, B.; Ichinose, Y.; Nishiwaki, Y.; Ohe, Y.; Yang, J. J.; Chewaskulyong, B.; Jiang, H.; Duffield, E. L.; Watkins, C. L.; Armour, A. A.; Fukuoka, M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med., 2009, 361, 947-57.
59. Tamura, K.; Okamoto, I.; Kashii, T.; Negoro, S.; Hirashima, T.; Kudoh, S.; Ichinose, Y.; Ebi, N.; Shibata, K.; Nishimura, T.; Katakami, N.; Sawa, T.; Shimizu, E.; Fukuoka, J.; Satoh, T.; Fukuoka, M.; West Japan Thoracic Oncology Group. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br. J. Cancer, 2008, 98, 907-14.
60. Sugio, K.; Uramoto, H.; Onitsuka, T.; Mizukami, M.; Ichiki, Y.; Sugaya, M.; Yasuda, M.; Takenoyama, M.; Oyama, T.; Hanagiri, T.; Yasumoto, K. Prospective phase II study of gefitinib in nonsmall cell lung cancer with epidermal growth factor receptor gene mutations. Lung Cancer, 2009, 64, 314-8.
61. Cappuzzo, F.; Ligorio, C.; Jänne, P. A.; Toschi, L.; Rossi, E.; Trisolini, R.; Paioli, D.; Holmes, A. J.; Magrini, E.; Finocchiaro, G.; Bartolini, S.; Cancellieri, A.; Ciardiello, F.; Patelli, M.; Crino, L.; Varella-Garcia, M. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridizationpositive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J. Clin. Oncol., 2007, 25, 2248-55.
62. Maemondo, M.; Inoue, A.; Kobayashi, K.; Sugawara, S.; Oizumi, S.; Isobe, H.; Gemma, A.; Harada, M.; Yoshizawa, H.; Kinoshita, I.; Fujita, Y.; Okinaga, S.; Hirano, H.; Yoshimori, K.; Harada, T.; Ogura, T.; Ando, M.; Miyazawa, H.; Tanaka, T.; Saijo, Y.; Hagiwara, K.; Morita, S.; Nukiwa, T.; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med., 2010, 362, 2380-8.
63. Bai, H.; Mao, L.; Wang, H. S.; Zhao, J.; Yang, L.; An, T. T.; Wang, X.; Duan, C. J.; Wu, N. M.; Guo, Z. Q.; Liu, Y. X.; Liu, H. N.; Wang, Y. Y.; Wang, J. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J. Clin. Oncol., 2009, 27, 2653-9.
64. Hidalgo, M.; Siu, L. L.; Nemunaitis, J.; Rizzo, J.; Hammond, L. A.; Takimoto, C.; Eckhardt, S. G.; Tolcher, A.; Britten, C. D.; Denis, L.; Ferrante, K.; Von Hoff, D. D.; Silberman, S.; Rowinsky, E. K. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol., 2001, 19, 3267-79.
65. Perez-Soler R. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in nonsmallcell lung cancer. Clin. Lung Cancer., 2004, 6, S20-3.
66. Giaccone, G.; Gallegos Ruiz, M.; Le Chevalier, T.; Thatcher, N.; Smit, E.; Rodriguez, J. A.; Janne, P.; Oulid-Aissa, D.; Soria, J. C. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin. Cancer Res., 2006, 12, 6049-55
67. Jackman, D. M.; Yeap, B. Y.; Lindeman, N. I.; Fidias, P.; Rabin, M. S.; Temel, J.; Skarin, A. T.; Meyerson, M.; Holmes, A. J.; Borras, A. M.; Freidlin, B.; Ostler, P. A.; Lucca, J.; Lynch, T. J.; Johnson, B. E.; Jänne, P. A. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J. Clin Oncol., 2007, 25, 760-6.
68. Shepherd, F. A.; Rodrigues Pereira, J.; Ciuleanu, T.; Tan, E. H.; Hirsh, V.; Thongprasert, S.; Campos, D.; Maoleekoonpiroj, S.; Smylie, M.; Martins, R.; van Kooten, M.; Dediu, M.; Findlay, B.; Tu, D.; Johnston, D.; Bezjak, A.; Clark, G.; Santabárbara, P.; Seymour, L.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med., 2005, 353, 123-32.
69. Herbst, R. S.; Prager, D.; Hermann, R.; Fehrenbacher, L.; Johnson, B. E.; Sandler, A.; Kris, M. G.; Tran, H. T.; Klein, P.; Li, X.; Ramies, D.; Johnson, D. H.; Miller, V. A.; TRIBUTE Investigator Group. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol., 2005, 23, 5892-9.
70. Gatzemeier, U.; Pluzanska, A.; Szczesna, A.; Kaukel, E.; Roubec, J.; De Rosa, F.; Milanowski, J.; Karnicka-Mlodkowski, H.; Pesek, M.; Serwatowski, P.; Ramlau, R.; Janaskova, T.; Vansteenkiste, J.; Strausz, J.; Manikhas, G. M.; Von Pawel, J. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol., 2007, 25, 1545-52.
71. Perng, R. P.; Yang, C. H.; Chen, Y. M.; Chang, G. C.; Lin, M. C.; Hsieh, R. K.; Chu, N. M.; Lai, R. S.; Su, W. C.; Tsao, C. J.; Hsia, T. C.; Chen, H. C.; Chen, C. H.; Huang, M. S.; Wang, J. L.; Ho, M. L.; Chung, C. Y.; Yu, C. J.; Chang, W. C.; Kuo, H. P.; Yu, C. T.; Lin, Z. Z.; Kao, W. Y. High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy. Lung Cancer, 2008, 62, 78-84.
72. Cedrés, S.; Prat, A.; Martínez, P.; Pallisa, E.; Sala, G.; Andreu, J.; Del Campo, J. M.; Quispe, I.; Baselga, J.; Felip, E. Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib. Lung Cancer, 2009, 66, 257-61.
73. Tsao, M. S.; Sakurada, A.; Cutz, J. C.; Zhu, C. Q.; Kamel-Reid, S.; Squire, J.; Lorimer, I.; Zhang, T.; Liu, N.; Daneshmand, M.; Marrano, P.; da Cunha Santos, G.; Lagarde, A.; Richardson, F.; Seymour, L.; Whitehead, M.; Ding, K.; Pater, J.; Shepherd, F. A. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med., 2005, 353, 133-44.
74. Zhu, C. Q.; da Cunha Santos, G.; Ding, K.; Sakurada, A.; Cutz, J. C.; Liu, N.; Zhang, T.; Marrano, P.; Whitehead, M.; Squire, J. A.; Kamel-Reid, S.; Seymour, L.; Shepherd, F. A.; Tsao, M. S. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol., 2008, 26, 4268-75.
75. Schneider, C. P.; Heigener, D.; Schott-von-Römer, K.; Gütz, S.; Laack, E.; Digel, W.; Guschall, W. R.; Franke, A.; Bodenstein, H.; Schmidtgen, C.; Reck, M. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study. J. Thorac. Oncol., 2008, 3, 1446-53.
76. Keohavong, P.; DeMichele, M. A.; Melacrinos, A. C.; Landreneau, R. J.; Weyant, R. J.; Siegfried J. M. Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin. Cancer Res., 1996, 2, 411-8.
77. Massarelli, E.; Varella-Garcia, M.; Tang, X.; Xavier, A. C.; Ozburn, N. C.; Liu, D. D.; Bekele, B. N.; Herbst, R. S.; Wistuba, I. I. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall-cell lung cancer. Clin Cancer Res., 2007, 13, 2890-6.
78. Pao, W.; Wang, T. Y.; Riely, G. J.; Miller, V. A.; Pan, Q.; Ladanyi, M.; Zakowski, M. F.; Heelan, R. T.; Kris, M. G.; Varmus, H. E. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med., 2005, 2, e17.
79. Pao, W.; Miller, V. A.; Politi, K. A.; Riely, G. J.; Somwar, R.; Zakowski, M. F.; Kris, M. G.; Varmus, H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med., 2005, 2, e73.
80. Kobayashi, S.; Boggon, T. J.; Dayaram, T.; Jänne, P. A.; Kocher, O.; Meyerson, M.; Johnson, B. E.; Eck, M. J.; Tenen, D. G.; Halmos, B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 2005, 352, 786-92.
81. Nguyen, K. S.; Kobayashi, S.; Costa, D. B. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmallcell lung cancers dependent on the epidermal growth factor receptor pathway. Clin. Lung Cancer, 2009, 10, 281-9.
82. Birchmeier, C.; Birchmeier, W.; Gherardi, E.; Vande Woude, G. F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell. Biol., 2003, 4, 915-25.
83. Sequist, LV. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist, 2007, 12, 325-30.
84. Kwak, E. L.; Sordella, R.; Bell, D. W.; Godin-Heymann, N.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Driscoll, D. R.; Fidias, P.; Lynch, T. J.; Rabindran, S. K.; McGinnis, J. P.; Wissner, A.; Sharma, S. V.; Isselbacher, K. J.; Settleman, J.; Haber, D. A. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. U. S. A., 2005, 102, 7665-70.
85. Scheurle, D.; Jahanzeb, M.; Aronsohn, R. S.; Watzek, L.; Narayanan, R. HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Hercep test. Anticancer Res., 2000, 20, 2091-6.
86. Tateishi, M.; Ishida, T.; Kohdono, S.; Hamatake, M.; Fukuyama, Y.; Sugimachi, K. Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma. Surg. Oncol., 1994, 3, 109-13.
87. Brabender, J.; Danenberg, K. D.; Metzger, R.; Schneider, P. M.; Park, J.; Salonga, D.; Hölscher, A. H.; Danenberg, P. V. Epidermal growth factor receptor and HER2-neu mRNA expression in nonsmall cell lung cancer Is correlated with survival. Clin Cancer Res., 2001, 7, 1850-5.
88. Wissner, A.; Overbeek, E.; Reich, M. F.; Floyd, M. B.; Johnson, B. D.; Mamuya, N.; Rosfjord, E. C.; Discafani, C.; Davis, R.; Shi, X.; Rabindran, S. K.; Gruber, B. C.; Ye, F.; Hallett, W. A.; Nilakantan, R.; Shen, R.; Wang, Y. F.; Greenberger, L. M.; Tsou, H. R. Synthesis and structure-activity relationships of 6, 7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J. Med. Chem., 2003, 46, 49-63.
89. Rabindran, S. K.; Discafani, C. M.; Rosfjord, E. C.; Baxter, M.; Floyd, M. B.; Golas, J.; Hallett, W. A.; Johnson, B. D.; Nilakantan, R.; Overbeek, E.; Reich, M. F.; Shen, R.; Shi, X.; Tsou, H. R.; Wang, Y. F.; Wissner, A. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res., 2004, 64, 3958-65.
90. Nunes, M.; Shi, C.; Greenberger, L. M.; Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes. Mol. Cancer Ther., 2004, 3, 21-7.
91. Erlichman, C.; Hidalgo, M.; Boni, J. P; Martins, P.; Quinn, S. E.; Zacharchuk, C.; Amorusi, P.; Adjei, A. A.; Rowinsky, E. K. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J. Clin. Oncol., 2006, 24, 2252-60
92. Yoshimura, N.; Kudoh, S.; Kimura, T.; Mitsuoka, S.; Matsuura, K.; Hirata, K.; Matsui, K.; Negoro, S.; Nakagawa, K.; Fukuoka, M. EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with nonsmall cell lung cancer with acquired resistance to gefitinib. Lung Cancer, 2006, 51, 363-8.
93. Wong, K. K.; Fracasso, P. M.; Bukowski, R. M.; Lynch, T. J.; Munster, P. N.; Shapiro, G. I.; Jänne, P. A.; Eder, J. P.; Naughton, M. J.; Ellis, M. J.; Jones, S. F.; Mekhail, T.; Zacharchuk, C.; Vermette, J.; Abbas, R.; Quinn, S.; Powell, C.; Burris, H. A. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin. Cancer Res., 2009, 15, 2552-8.
94. Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. F.; Shapiro, G. I.; Baum, A.; Himmelsbach, F.; Rettig, W. J.; Meyerson, M.; Solca, F.; Greulich, H.; Wong, K. K. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene, 2008, 27, 4702-11.
95. Perera, S. A.; Li, D.; Shimamura, T.; Raso, M. G.; Ji, H.; Chen, L.; Borgman, C. L.; Zaghlul, S.; Brandstetter, K. A.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. F.; Bronson, R. T.; Shapiro, G. I.; Greulich, H.; Meyerson, M.; Guertler, U.; Chesa, P. G.; Solca, F.; Wistuba, I. I.; Wong, K. K. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc. Natl. Acad. Sci. U. S. A., 2009, 106, 474-9.
96. Eskens, F. A.; Mom, C. H.; Planting, A. S.; Gietema, J. A.; Amelsberg, A.; Huisman, H.; van Doorn, L.; Burger, H.; Stopfer, P.; Verweij, J.; de Vries, E. G. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br. J. Cancer., 2008, 98, 80-5.
97. Allen, L. F.; Eiseman, I. A.; Fry, D. W.; Lenehan, P. F. CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer. Semin. Oncol., 2003, 30 (Suppl 16), 65-78.
98. Slichenmyer, W. J.; Elliott, W. L.; Fry, D. W. CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin. Oncol., 2001, 28 (Suppl 16), 80-5.
99. Nemunaitis, J.; Eiseman, I.; Cunningham, C.; Senzer, N.; Williams, A.; Lenehan, P. F.; Olson, S. C.; Bycott, P.; Schlicht, M.; Zentgraff, R.; Shin, D. M.; Zinner, R. G. Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer. Clin. Cancer Res., 2005, 11, 3846-53.
100. Garland, L. L.; Hidalgo, M.; Mendelson, D. S.; Ryan, D. P.; Arun, B. K.; Lovalvo, J. L.; Eiseman, I. A.; Olson, S. C.; Lenehan, P. F.; Eder, J. P. A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors. Clin. Cancer Res., 2006, 12, 4274-82.
101. Jänne, P. A.; von Pawel, J.; Cohen, R. B.; Crino, L.; Butts, C. A.; Olson, S. S.; Eiseman, I. A.; Chiappori, A. A.; Yeap, B. Y.; Lenehan, P. F.; Dasse, K.; Sheeran, M.; Bonomi, P. D. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. J. Clin. Oncol., 2007, 25, 3936-44.
102. Chiappori, A. A.; Ellis, P. M.; Hamm, J. T.; Bitran, J. D.; Eiseman, I.; Lovalvo, J.; Burnett, D.; Olson, S.; Lenehan, P.; Zinner, R. G. A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer. J. Thorac. Oncol., 2006, 1, 1010-9.
103. Rusnak, D. W.; Lackey, K.; Affleck, K.; Wood, E. R.; Alligood, K. J.; Rhodes, N.; Keith, B. R.; Murray, D. M.; Knight, W. B.; Mullin, R. J.; Gilmer, T. M. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther., 2001, 1, 85-94.
104. Xia, W.; Mullin, R. J.; Keith, B. R.; Liu, L. H.; Ma, H.; Rusnak, D. W.; Owens, G.; Alligood, K. J.; Spector, N. L. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene, 2002, 21, 6255-63
105. Medina, P. J.; Goodin, S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin. Ther., 2008, 30, 1426-47.
106. Geyer, C. E.; Forster, J.; Lindquist, D.; Chan, S.; Romieu, C. G.; Pienkowski, T.; Jagiello-Gruszfeld, A.; Crown J.; Chan, A.; Kaufman, B.; Skarlos, D.; Campone, M.; Davidson, N.; Berger, M.; Oliva, C.; Rubin, S. D.; Stein, S.; Cameron, D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med., 2006, 355, 2733-43.
107. Kim, H. P.; Han, S. W.; Kim, S. H.; Im, S. A.; Oh, D. Y.; Bang, Y. J.; Kim T. Y. Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells. Mol. Cancer Ther., 2008, 7, 607-15.
108. Mendelsohn, J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin. Cancer Res., 1997, 3, 2703-7.
109. Goldstein, N. I.; Prewett, M.; Zuklys, K.; Rockwell, P.; Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res., 1995, 1, 1311-8.
110. Baselga, J.; Pfister, D.; Cooper, M. R.; Cohen, R.; Burtness, B.; Bos, M.; D'Andrea, G.; Seidman, A.; Norton, L.; Gunnett, K.; Falcey, J.; Anderson, V.; Waksal, H.; Mendelsohn, J. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol., 2000, 18, 904-14.
111. Rosell, R.; Robinet, G.; Szczesna, A.; Ramlau, R.; Constenla, M.; Mennecier, B. C.; Pfeifer, W.; O'Byrne, K. J.; Welte, T.; Kolb, R.; Pirker, R.; Chemaissani, A.; Perol, M.; Ranson, M. R.; Ellis, P. A.; Pilz, K.; Reck, M. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann. Oncol., 2008, 19, 362-9.
112. Butts, C. A.; Bodkin, D.; Middleman, E. L.; Englund, C. W.; Ellison, D.; Alam, Y.; Kreisman, H.; Graze, P.; Maher, J.; Ross, H. J.; Ellis, P. M.; McNulty, W.; Kaplan, E.; Pautret, V.; Weber, M. R.; Shepherd F. A. Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J. Clin. Oncol., 2007, 25, 5777-84.
113. Pirker, R.; Pereira, J. R.; Szczesna, A.; von Pawel, J.; Krzakowski, M.; Ramlau, R.; Vynnychenko, I.; Park, K.; Yu, C. T.; Ganul, V.; Roh, J. K.; Bajetta, E.; O'Byrne, K.; de Marinis, F.; Eberhardt, W.; Goddemeier, T.; Emig, M.; Gatzemeier, U.; FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced nonsmallcell lung cancer (FLEX): an open-label randomised phase III trial. Lancet, 2009, 373, 1525-31.
114. Lynch, T. J.; Patel, T.; Dreisbach, L.; McCleod, M.; Heim, W. J.; Hermann, R. C.; Paschold, E.; Iannotti, N. O.; Dakhil, S.; Gorton, S.; Pautret, V.; Weber, M. R.; Woytowitz, D. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J. Clin. Oncol., 2010, 28, 911-7.
115. Khambata-Ford, S.; Harbison, C. T.; Hart, L. L.; Awad, M.; Xu, L. A.; Horak, C. E.; Dakhil, S.; Hermann, R. C.; Lynch, T. J.; Weber, M. R. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol., 2010, 28, 918-27.
116. Kim, E. S.; Mauer, A. M.; William, W. N Jr.; Tran, H. T.; Liu, D.; Lee, J. J.; Windt, P.; Hong, W. K.; Vokes, E. E.; Herbst, R. S. A phase 2 study of cetuximab in combination with docetaxel in chemotherapyrefractory/resistant patients with advanced nonsmall cell lung cancer. Cancer, 2009, 115, 1713-22.
117. Jalal, S.; Waterhouse, D.; Edelman, M. J.; Nattam, S.; Ansari, R.; Koneru, K.; Clark, R.; Richards, A.; Wu, J.; Yu, M.; Bottema, B.; White, A.; Hanna, N. Pemetrexed plus Cetuximab in Patients with Recurrent Non-small Cell Lung Cancer (NSCLC): A Phase I/II Study from the Hoosier Oncology Group. J. Thorac. Oncol., 2009. [Epub ahead of print]
118. Dittmann, K.; Mayer, C.; Rodemann, H. P. Inhibition of radiationinduced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother. Oncol., 2005, 76, 157-61.
119. Bonner, J. A.; Harari, P. M.; Giralt, J.; Azarnia, N.; Shin, D. M.; Cohen, R. B.; Jones, C. U.; Sur, R.; Raben, D.; Jassem, J.; Ove, R.; Kies, M. S.; Baselga, J.; Youssoufian, H.; Amellal, N.; Rowinsky, E. K.; Ang, K. K. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med., 2006, 354, 567-78
120. Hughes, S.; Liong, J.; Miah, A.; Ahmad, S.; Leslie, M.; Harper, P.; Prendiville, J.; Shamash, J.; Subramaniam, R.; Gaya, A.; Spicer, J.; Landau, D. A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study. J. Thorac. Oncol., 2008, 3, 648-51.
121. Huang, S.; Armstrong, E. A.; Benavente, S.; Chinnaiyan, P.; Harari, P. M. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res., 2004, 64, 5355-62.
122. Ramalingam, S.; Forster, J.; Naret, C.; Evans, T.; Sulecki, M.; Lu, H.; Teegarden, P.; Weber, M. R.; Belani, C. P. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. J. Thorac. Oncol., 2008, 3, 258-64.
123. Yang, X. D.; Jia, X. C.; Corvalan, J. R.; Wang, P.; Davis, C. G. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit. Rev. Oncol. Hematol., 2001, 38, 17-23.
124. Foon, K. A.; Yang, X. D.; Weiner, L. M.; Belldegrun, A. S.; Figlin R. A.; Crawford, J.; Rowinsky, E. K.; Dutcher, J. P.; Vogelzang, N. J.; Gollub, J.; Thompson, J. A.; Schwartz, G.; Bukowski, R. M.; Roskos, L. K.; Schwab, G. M. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int. J. Radiat. Oncol. Biol. Phys., 2004, 58, 984-90.
125. Weiner, L. M.; Belldegrun, A. S.; Crawford, J.; Tolcher, A. W.; Lockbaum, P.; Arends, R. H.; Navale, L.; Amado, R. G.; Schwab, G.; Figlin, R. A. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin. Cancer Res., 2008, 14, 502-8.
126. Socinski, M. A. Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab. Clin. Cancer Res., 2007, 13, s4597-601.
127. Kollmannsberger, C.; Schittenhelm, M.; Honecker, F.; Tillner, J.; Weber, D.; Oechsle, K.; Kanz, L.; Bokemeyer, C. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced nonsmallcell lung cancer (NSCLC). Ann. Oncol., 2006, 17, 1007-13.
128. Schittenhelm, M. M.; Kollmannsberger, C.; Oechsle, K.; Harlow, A.; Morich, J.; Honecker, F.; Kurek, R.; Störkel, S.; Kanz, L.; Corless, C. L.; Wong, K. K.; Bokemeyer, C.; Heinrich M. C. Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer. Mol. Cancer Ther., 2009, 8, 481-9.
129. Kim, K. J.; Li, B.; Winer, J.; Armanini, M.; Gillett, N.; Phillips, H. S.; Ferrara, N. Inhibition of vascular endothelial growth factorinduced angiogenesis suppresses tumour growth in vivo. Nature, 1993, 362, 841-4.
130. Neufeld, G.; Cohen, T.; Gengrinovitch, S.; Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J., 1999, 13, 9-22.
131. Stone, J.; Itin, A.; Alon, T.; Pe'er, J.; Gnessin, H.; Chan-Ling, T.; Keshet, E. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J. Neurosci., 1995, 15, 4738-47.
132. Rak, J.; Mitsuhashi, Y.; Bayko, L.; Filmus, J.; Shirasawa, S.; Sasazuki, T.; Kerbel, R. S. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res., 1995, 55, 4575-80.
133. Kieser, A.; Weich, H. A.; Brandner, G.; Marmé, D.; Kolch, W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene, 1994, 9, 963-9.
134. Presta, L. G.; Chen, H.; O'Connor, S. J.; Chisholm, V.; Meng, Y. G.; Krummen, L.; Winkler, M.; Ferrara, N. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res., 1997, 57, 4593-9.
135. Gordon, M. S.; Margolin, K.; Talpaz M.; Sledge, G. W. Jr.; Holmgren, E.; Benjamin, R.; Stalter, S.; Shak, S.; Adelman, D. Phase I safety and pharmacokinetic study of recombinant human antivascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol., 2001, 19, 843-50.
136. Johnson, D. H.; Fehrenbacher, L.; Novotny, W. F.; Herbst, R. S.; Nemunaitis, J. J.; Jablons, D. M.; Langer, C. J.; DeVore, R. F. 3rd.; Gaudreault, J.; Damico, L. A.; Holmgren, E.; Kabbinavar, F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol., 2004, 22, 2184-91.
137. Sandler, A.; Gray, R.; Perry, M. C.; Brahmer, J.; Schiller J. H.; Dowlati, A.; Lilenbaum, R.; Johnson, D. H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med., 2006, 355, 2542-50.
138. Brahmer, J. R.; Gray, R.; Schiller, J. H.; Perry M.; Sandler, A.; Johnson, D. ECOG 4599 phase III trial of carboplatin and paclitaxel ±bevacizumab: Subset analysis of survival by gender. J. Clin. Oncol., 2006, 24, abstr 7036.
139. Wakelee, H. A.; Dahlberg, S. E.; Brahmer, J. R.; Schiller, J. H.; Perry, M. C.; Langer, C. J.; Sandler, A. B.; Belani, C. P.; Johnson, D. H. Increased benefit from bevacizumab (BEV) in younger women with advanced NSCLC on Eastern Cooperative Oncology Group (ECOG) E4599. J. Thorac. Oncol., 2008, 3, abstr 131.
140. Ramalingam, S. S.; Dahlberg, S. E.; Langer, C. J.; Gray, R.; Belani, C. P.; Brahmer, J. R.; Sandler, A.; Schiller, J. H.; Johnson, D. H. Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): Analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study. J. Clin. Oncol., 2007, 25, abstr 7535.
141. Reck, M.; von Pawel, J.; Zatloukal, P.; Ramlau, R.; Gorbounova, V.; Hirsh, V.; Leighl, N.; Mezger, J.; Archer, V.; Moore, N.; Manegold, C. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J. Clin. Oncol., 2009, 27, 1227-34.
142. Reck, M.; von Pawel, J.; Zatloukal, P.; Ramlau, R.; Gorbounova, V.; Hirsh, V.; Leighl, N.; Mezger, J.; Archer, V.; Moore, N. Manegold C; BO17704 Study Group. Overall survival with cisplatingemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann. Oncol., 2010 [Epub ahead of print].
143. Lilenbaum, R.; Raez, L.; Tseng, J.; Seigel, L.; Davila, E. Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer. J. Thorac. Oncol., 2008, 3, 511-5.
144. Patel, J. D.; Hensing, T. A.; Rademaker, A.; Hart, E. M.; Blum, M. G.; Milton, D. T.; Bonomi, P. D. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-smallcell lung cancer. J. Clin. Oncol., 2009, 27, 3284-9.
145. Patel, J. D.; Bonomi, P.; Socinski, M. A.; Govindan, R.; Hong, S.; Obasaju, C.; Pennella, E. J.; Girvan, A. C.; Guba, S. C. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-smallcell lung cancer. Clin. Lung Cancer, 2009, 10, 252-6.
146. Heist, R. S.; Fidias, P.; Huberman, M.; Ardman, B.; Sequist, L. V.; Temel, J. S.; Lynch, T. J. A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced nonsmall cell lung cancer. J. Thorac. Oncol., 2008, 3, 1153-8.
147. Herbst, R. S.; Johnson, D. H.; Mininberg, E.; Carbone, D. P.; Henderson, T.; Kim, E. S.; Blumenschein, G. Jr.; Lee, J. J.; Liu, D. D.; Truong, M. T.; Hong, W. K.; Tran, H.; Tsao, A.; Xie, D.; Ramies, D. A.; Mass, R.; Seshagiri, S.; Eberhard, D. A.; Kelley, S. K.; Sandler, A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol., 2005, 23, 2544-55.
148. Herbst, R. S.; O'Neill, V. J.; Fehrenbacher, L.; Belani, C. P.; Bonomi, P. D.; Hart, L.; Melnyk, O.; Ramies, D.; Lin, M.; Sandler A. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J. Clin. Oncol., 2007, 25, 4743-50.
149. Hainsworth, J.; Herbst, R. A phase III, multicenter, placebocontrolled, double-blind, randomized clinical trial to evaluate the efficacy of Bevacizumab (Avastin®) in combination with Erlotinib (Tarceva®) compared with erlotinib alone for treatment of advanced non-small cell lung cancer after failure of standard first-line chemotherapy (BETA). J. Thorac. Oncol., 2008, 3, S302.
150. Miller, V. A.; O'Connor, P.; Soh, C.; Kabbinavar, F. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol., 2009, 27, LBA8002.
151. Socinski, M. A.; Langer, C. J.; Huang, J. E.; Kolb, M. M.; Compton, P.; Wang, L.; Akerley, W. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J. Clin. Oncol., 2009, 27, 5255-61.
152. Besse, B.; Lasserre, S. F.; Compton, P.; Huang, J.; Augustus, S.; Rohr, U. P. Bevacizumab Safety in Patients with Central Nervous System Metastases. Clin. Cancer Res., 2010, 16, 269-278.
153. Mendel, D. B.; Laird, A. D.; Xin, X.; Louie, S. G.; Christensen, J. G.; Li, G.; Schreck, R. E.; Abrams, T. J.; Ngai, T. J.; Lee, L. B.; Murray, L. J.; Carver, J.; Chan, E.; Moss, K. G.; Haznedar, J. O.; Sukbuntherng, J.; Blake, R. A.; Sun, L.; Tang, C.; Miller, T.; Shirazian, S.; McMahon, G.; Cherrington, J. M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res., 2003, 9, 327-37.
154. O'Farrell, A. M.; Abrams, T. J.; Yuen, H. A.; Ngai, T. J.; Louie, S. G.; Yee, K. W.; Wong, L. M.; Hong, W.; Lee, L. B.; Town, A.; Smolich, B. D.; Manning, W. C.; Murray, L. J.; Heinrich, M. C.; Cherrington, J. M. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood, 2003, 101, 3597-605.
155. Faivre, S.; Delbaldo, C.; Vera, K.; Robert, C.; Lozahic, S.; Lassau, N.; Bello, C.; Deprimo, S.; Brega, N.; Massimini, G.; Armand, J. P.; Scigalla, P.; Raymond, E. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol., 2006, 24, 25-35.
156. Socinski, M. A.; Novello, S.; Brahmer, J. R.; Rosell, R.; Sanchez, J. M.; Belani, C. P.; Govindan, R.; Atkins, J. N.; Gillenwater, H. H.; Pallares, C.; Tye, L.; Selaru, P.; Chao, R. C.; Scagliotti, G. V. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J. Clin. Oncol., 2008, 26, 650-6.
157. Wilhelm, S. M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L. E.; Bollag, G.; Trail, P. A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res., 2004, 64, 7099-109.
158. Strumberg, D.; Clark, J. W.; Awada, A.; Moore, M. J.; Richly, H.; Hendlisz, A.; Hirte, H. W.; Eder, J. P.; Lenz, H. J.; Schwartz, B. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist, 2007, 12, 426-37.
159. Blumenschein, G. R. Jr.; Gatzemeier, U.; Fossella, F.; Stewart, D. J.; Cupit, L.; Cihon, F.; O'Leary, J.; Reck, M. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J. Clin. Oncol., 2009, 27, 4274-80.
160. Schiller, J. H.; Lee, J. W.; Hanna, N. H.; Traynor, A. M.; Carbone, D. P. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. J. Clin. Oncol.; 2008, 26, abstr 8014.
161. Dingemans, A. M.; van Wijk, A.; Hochstenbag, M.; Thunnissen, E.; Meulemans, E.; Smit, E. F. Sorafenib in pretreated patients with advanced non-small lung cancer harbouring a K-ras mutation. J. Thorac. Oncol., 2009, 4, abstr D.10.6.
162. Cho, B.; Kim, S.; Heo, D. S.; Kang, S.; Kim, H.; Lee, D.; Kim, D.; Jung, M.; Choi, J.; Kim, J. A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced nonsmall cell lung cancer (NSCLC). J. Clin. Oncol.; 2010, 28, abstr 7547.
163. Lind, J. S.; Dingemans, A. M.; Groen, H. J.; Thunnissen, F. B.; Bekers, O.; Heideman, D. A.; Honeywell, R. J.; Giovannetti, E.; Peters, G. J.; Postmus, P. E.; van Suylen, R. J.; Smit, E. F. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Clin. Cancer Res., 2010, 16, 3078-87.
164. Ciardiello, F.; Caputo, R.; Damiano, V.; Caputo, R.; Troiani, T.; Vitagliano, D.; Carlomagno, F.; Veneziani, B. M.; Fontanini, G.; Bianco, A. R.; Tortora, G. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res., 2003, 9, 1546-56.
165. Ciardiello, F.; Bianco, R.; Caputo, R.; Caputo, R.; Damiano, V.; Troiani, T.; Melisi, D.; De Vita, F.; De Placido, S.; Bianco, A. R.; Tortora, G. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin. Cancer Res., 2004, 10, 784-93.
166. Holden, S. N.; Eckhardt, S. G.; Basser, R.; de Boer, R.; Rischin, D.; Green, M.; Rosenthal, M. A.; Wheeler, C.; Barge, A.; Hurwitz, H. I. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signalling, in patients with solid, malignant tumors. Ann. Oncol., 2005, 16, 1391-7.
167. Heymach, J. V.; Johnson, B. E.; Prager, D.; Csada, E.; Roubec, J.; Pesek, M.; Spásová, I.; Belani, C. P.; Bodrogi, I.; Gadgeel, S.; Kennedy, S. J.; Hou, J.; Herbst, R. S. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J. Clin. Oncol., 2007, 25, 4270-7.
168. Natale, R. B.; Bodkin, D.; Govindan, R.; Sleckman, B. G.; Rizvi, N. A.; Capó, A.; Germonpré, P.; Eberhardt, W. E.; Stockman, P. K.; Kennedy, S. J.; Ranson, M. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J. Clin. Oncol., 2009, 27, 2523-9
169. Heymach, J. V.; Paz-Ares, L.; De Braud, F.; Sebastian, M.; Stewart, D. J.; Eberhardt, W. E.; Ranade, A. A.; Cohen, G.; Trigo, J. M.; Sandler, A. B.; Bonomi, P. D.; Herbst, R. S.; Krebs, A. D.; Vasselli, J.; Johnson, B. E. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J. Clin. Oncol., 2008, 26, 5407-5415.
170. Natale, R. B.; Thongprasert, S.; Greco, F. A.; Thomas, M.; Tsai, C. M.; Sunpaweravong, P.; Ferry, D.; Langmuir, P.; Rowbottom, J. A.; Goss, G. D. Vandetanib versus erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) after failure of at least 1 prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST). J. Clin. Oncol., 2009, 27, abstr 8009.
171. De Boer, R.; Arrieta, Ó.; Gottfried, M.; Blackhall, F. H.; Raats, J.; Yang, C. H.; Langmuir, P.; Milenkova, T.; Read, J.; Vansteenkiste, J. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL). J. Clin. Oncol., 2009, 27, abstr 8010.
172. Herbst, R. S.; Sun, Y.; Eberhardt, W. E.; Germonpré, P.; Saijo, N.; Zhou, C.; Wang, J.; Li, L.; Kabbinavar, F.; Ichinose, Y.; Qin, S.; Zhang, L.; Biesma, B.; Heymach, J. V.; Langmuir, P.; Kennedy, S. J.; Tada, H.; Johnson, B. E. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced nonsmallcell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol., 2010, 11, 619-626.
173. Wedge, S. R.; Kendrew, J.; Hennequin, L. F.; Valentine, P. J.; Barry, S. T.; Brave, S. R.; Smith, N. R.; James, N. H.; Dukes, M.; Curwen, J. O.; Chester, R.; Jackson, J. A.; Boffey, S. J.; Kilburn, L. L.; Barnett, S.; Richmond, G. H.; Wadsworth P. F.; Walker, M.; Bigley, A. L.; Taylor, S. T.; Cooper, L.; Beck, S.;, Jürgensmeier, J. M.; Ogilvie, D. J. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res., 2005, 65, 4389-400.
174. Laurie, S. A.; Gauthier, I.; Arnold, A.; Shepherd, F. A.; Ellis, P. M.; Chen, E.; Goss, G.; Powers, J.; Walsh, W.; Tu, D.; Robertson, J.; Puchalski, T. A.; Seymour, L. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J. Clin. Oncol., 2008, 26, 1871-8.
175. Goss, G.; Shepherd, F. A.; Laurie, S.; Gauthier, I.; Leighl, N.; Chen, E.; Feld, R.; Powers, J.; Seymour, L. A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. Eur. J. Cancer, 2009, 45, 782-8
176. Goss, G. D.; Arnold, A.; Shepherd, F. A.; Dediu, M.; Ciuleanu, T. E.; Fenton, D.; Zukin, M.; Walde, D.; Laberge, F.; Vincent, M. D.; Ellis, P. M.; Laurie, S. A.; Ding, K.; Frymire, E.; Gauthier, I.; Leighl, N. B.; Ho, C.; Noble, J.; Lee, C. W.; Seymour, L. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J. Clin. Oncol., 2010, 28, 49-55.
177. Kumar, R.; Knick, V. B.; Rudolph, S. K.; Johnson, J. H.; Crosby, R. M.; Crouthamel, M. C.; Hopper, T. M.; Miller, C. G.; Harrington, L. E.; Onori, J. A.; Mullin, R. J.; Gilmer, T. M.; Truesdale, A. T.; Epperly, A. H.; Boloor, A.; Stafford, J. A.; Luttrell, D. K.; Cheung, M. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol. Cancer Ther., 2007, 6, 2012-21.
178. Hurwitz, H. I.; Dowlati, A.; Saini, S.; Savage, S.; Suttle, A. B.; Gibson, D. M.; Hodge, J. P.; Merkle, E. M.; Pandite, L. Phase I trial of pazopanib in patients with advanced cancer. Clin. Cancer Res., 2009, 15, 4220-7.
179. Inai, T.; Mancuso, M.; Hashizume, H.; Baffert, F.; Haskell, A.; Baluk, P.; Hu-Lowe, D. D.; Shalinsky, D. R.; Thurston, G.; Yancopoulos, G. D.; McDonald, D. M. Inhibition of vascular endothelial growth factor (VEGF) signalling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol., 2004, 165, 35-52.
180. Rugo, H. S.; Herbst, R. S.; Liu, G.; Park, J. W.; Kies, M. S.; Steinfeldt, H. M.; Pithavala, Y. K.; Reich, S. D.; Freddo, J. L.; Wilding, G. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J. Clin. Oncol., 2005, 23, 5474-83.
181. Schiller, J. H.; Larson, T.; Ou, S. H.; Limentani, S.; Sandler, A.; Vokes, E.; Kim, S.; Liau, K.; Bycott, P.; Olszanski, A. J.; von Pawel, J. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J. Clin. Oncol., 2009, 27, 3836-41.
182. Polverino, A.; Coxon, A.; Starnes, C.; Diaz, Z.; DeMelfi, T.; Wang, L.; Bready, J.; Estrada, J.; Cattley, R.; Kaufman, S.; Chen, D.; Gan, Y.; Kumar, G.; Meyer, J.; Neervannan, S.; Alva, G.; Talvenheimo, J.; Montestruque, S.; Tasker, A.; Patel, V.; Radinsky, R.; Kendall, R. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res., 2006, 66, 8715-21.
183. Price, T. J.; Lipton, L.; McGreivy, J.; McCoy, S.; Sun, Y. N.; Rosenthal, M. A. Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours. Br. J. Cancer, 2008, 99, 1387-94.
184. http://www.medscape.com/viewarticle/584015 (last accessed 20/06/2010).
185. http://wwwext.amgen.com/media/media-pr-detail.jsp?year= 2009&releaseID=1255738 (last accessed 20/06/2010).
186. Wakelee, H. A.; Fehling, J. M.; Molina, J. R.; Lensing, J. L.; Funke, R. P.; Miles, D.; Sikic, B. I. A phase I study of XL647, an EGFR, HER2, VEGFR2 inhibitor, administered orally daily to patients (pts) with advanced solid malignancies (ASM). J. Clin. Oncol., 2008, 26, abstr 3528.
187. Miller, V. A.; Wakelee, H. A.; Lara, P. N.; Cho, J.; Chowhan, N. M.; Costa, D.; Vrindavanam, N.; Yanagihara, R.; Pennell, N.; Lynch, T. J. Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: Preliminary results of a phase II trial. J. Clin. Oncol., 2008, 26, abstr 8028.
188. Teicher, B. A.; Alvarez, E.; Menon, K.; Esterman, M. A.; Considine, E.; Shih, C.; Faul, M. M. Antiangiogenic effects of a protein kinase Cbeta-selective small molecule. Cancer Chemother. Pharmacol., 2002, 49, 69-77.
189. Carducci, M. A.; Musib, L.; Kies, M. S.; Pili, R.; Truong, M.; Brahmer, J. R.; Cole, P.; Sullivan, R.; Riddle, J.; Schmidt, J.; Enas, N.; Sinha, V.; Thornton, D. E.; Herbst, R. S. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J. Clin. Oncol., 2006, 24, 4092-9.
190. Oh, Y.; Herbst, R. S.; Burris, H.; Cleverly, A.; Musib, L.; Lahn, M.; Bepler, G. Enzastaurin, an oral serine/threonine kinase inhibitor, as second-or third-line therapy of non-small-cell lung cancer. J. Clin. Oncol., 2008, 26, 1135-41.
191. Chiappori, A.; Bepler, G.; Barlesi, F.; Soria, J. C.; Reck, M.; Bearz, A.; Barata, F.; Scagliotti, G.; Park, K.; Wagle, A.; Liepa, A. M.; Zhao, Y. D.; Chouaki, N.; Iscoe, N.; von Pawel, J. Phase II, doubleblinded, randomized study of enzastaurin plus pemetrexed as secondline therapy in patients with advanced non-small cell lung cancer. J. Thorac. Oncol., 2010, 5, 369-75.
192. Wood, J. M.; Bold, G.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Frei, J.; Hofmann, F.; Mestan, J.; Mett, H.; O'Reilly, T.; Persohn, E.; Rösel, J.; Schnell, C.; Stover, D.; Theuer, A.; Towbin, H.; Wenger, F.; Woods-Cook, K.; Menrad, A.; Siemeister, G.; Schirner, M.; Thierauch, K. H.; Schneider, M. R.; Drevs, J.; Martiny-Baron, G.; Totzke, F. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res., 2000, 60, 2178-89.
193. Drevs, J.; Hofmann, I.; Hugenschmidt, H.; Wittig, C.; Madjar, H.; Müller, M.; Wood, J.; Martiny-Baron, G.; Unger, C.; Marmé, D. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res., 2000, 60, 4819-24.
194. Thomas, A. L.; Morgan, B.; Horsfield, M. A.; Higginson, A.; Kay, A.; Lee, L.; Masson, E.; Puccio-Pick, M.; Laurent, D.; Steward, W. P. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J. Clin. Oncol., 2005, 23, 4162-71.
195. Chiorean, E. G.; Malireddy, S.; Younger, A. E.; Jones, D. R.; Waddell, M. J.; Sloop, M. I.; Yu, M.; Hall, S. D.; Schneider, B.; Sweeney, C. J. A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors. Cancer Chemother. Pharmacol., 2010, 66, 441-8.
196. Langenberg, M. H.; Witteveen, P. O.; Lankheet, N. A.; Roodhart, J. M.; Rosing, H.; van den Heuvel, I. J.; Beijnen, J. H.; Voest, E. E. Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis. Neoplasia, 2010, 12, 206-13.
197. Los, M.; Roodhart, J. M.; Voest, E. E. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist, 2007, 12, 443-50.
198. O'Reilly, M. S.; Boehm, T.; Shing, Y.; Fukai, N.; Vasios, G.; Lane, W. S.; Flynn, E.; Birkhead, J. R.; Olsen, B. R.; Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 1997, 88, 277-85.
199. Herbst, R. S.; Hess, K. R.; Tran, H. T.; Tseng, J. E.; Mullani, N. A.; Charnsangavej, C.; Madden, T.; Davis, D. W.; McConkey, D. J.; O'Reilly, M. S.; Ellis, L. M.; Pluda, J.; Hong, W. K.; Abbruzzese, J. L. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Onc., 2002, 20, 3792-3803.
200. Hansma, A. H.; Broxterman, H. J.; van der Horst, I.; Yuana, Y.; Boven, E.; Giaccone, G.; Pinedo, H. M.; Hoekman, K. Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. Ann. Oncol., 2005, 16, 1695-701.
201. Yang, L.; Wang, J. W.; Sun, Y.; Zhu, Y. Z.; Liu, X. Q.; Li, W. L.; Di, L. J.; Li, P. W.; Wang, Y. L.; Song, S. P.; Yao, C.; You, L. F. Randomized phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi, 2006, 28, 138-41.
202. Qi, D. L.; Yang, Y. Z.; Liu, Z. J.; Wang, Q. S.; Xin, L.; Cui, Y.; Qiao, Y. F.; Feng, K. rh-endostatin in combination with docetaxel and carboplatin as adjuvant treatment for non-small lung cancer. Zhonghua Yi Xue Za Zhi, 2009, 89, 1057-9.
203. Huang, G.; Chen, L. Discrepancies between antiangiogenic and antitumor effects of recombinant human endostatin. Cancer Biother. Radiopharm., 2009, 24, 589-96.
204. Riely, G. J.; Miller, V. A. Vascular endothelial growth factor trap in non small cell lung cancer. Clin. Cancer Res., 2007, 13, s4623-7.
205. Holash, J.; Davis, S.; Papadopoulos, N.; Croll, S. D.; Ho, L.; Russell, M.; Boland, P.; Leidich, R.; Hylton, D.; Burova, E.; Ioffe, E.; Huang, T.; Radziejewski, C.; Bailey, K.; Fandl, J. P.; Daly, T.; Wiegand, S. J.; Yancopoulos, G. D.; Rudge, J. S. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci., U. S. A., 2002, 99, 11393-8.
206. Dupont, J.; Schwartz, L.; Koutcher, J.; Spriggs, D.; Gordon, M.; Mendelson, D.; Murren, J.; Lucarelli, A.; Cedarbaum, J. Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies. J. Clin. Oncol., 2004;22, abstr 3009.
207. Dupont, J.; Rothenberg, M. L.; Spriggs, D. R.; Cedarbaum, J. M.; Furfine, E. S.; Cohen, D. P.; Dancy, I.; Lee, H. S.; Cooper, W.; Lockhart, A. C. Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors. J. Clin. Oncol., 2005, 23, abstr 3029.
208. Massarelli, E., Miller, V. A.; Leighl, N. B.; Rosen, P. J.; Albain, K. S.; Hart, L. L.; Melnyk, O.; Sternas, L.; Ackerman, J.;. Herbst, R. S. Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum-and erlotinib-resistant adenocarcinoma of the lung (NSCLA). J. Clin. Oncol., 2007, 25, abstr 7627
209. Leighl, N. B.; Raez, L. E.; Besse, B.; Rosen, P. J.; Barlesi, F.; Massarelli, E.; Gabrail, N.; Hart, L. L.; Albain, K. S.; Berkowitz, L.; Melnyk, O.; Shepherd, F. A.; Sternas, L.; Ackerman, J.; Shun, Z.; Miller, V. A.; Herbst, R. S. A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum-and erlotinibresistant adenocarcinoma of the lung. J. Thorac. Oncol., 2010, 5, 1054-9.
210. Le Roith, D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N. Engl. J. Med., 1997, 336, 633-40.
211. Ma, W. W.; Adjei, A. A. Novel agents on the horizon for cancer therapy. CA. Cancer J. Clin., 2009, 59, 111-37.
212. Havemann, K.; Rotsch, M.; Schöneberger, H. J.; Erbil, C.; Hennig, C.; Jaques, G. Growth regulation by insulin-like growth factors in lung cancer. J. Steroid Biochem. Mol. Biol., 1990, 37, 877-82.
213. Ouban, A.; Muraca, P.; Yeatman, T.; Coppola, D. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum. Pathol., 2003, 34, 803-8.
214. Moorehead, R. A.; Sanchez, O. H.; Baldwin, R. M.; Khokha, R. Transgenic overexpression of IGF-II induces spontaneous lung tumors: a model for human lung adenocarcinoma. Oncogene, 2003, 22, 853-7.
215. Cosaceanu, D.; Carapancea, M.; Alexandru, O.; Budiu, R.; Martinsson, H. S.; Starborg, M.; Vrabete, M.; Kanter, L.; Lewensohn, R..; Dricu, A. Comparison of three approaches for inhibiting insulinlike growth factor I receptor and
216. Ji, Q. S.; Mulvihill, M. J.; Rosenfeld-Franklin, M.; Cooke, A.; Feng, L.; Mak, G.; O'Connor, M.; Yao, Y.; Pirritt, C.; Buck, E.; Eyzaguirre, A.; Arnold, L. D.; Gibson, N. W. Pachter, J. A. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signalling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Mol. Cancer Ther., 2007, 6, 2158-67.
217. Cohen, B. D.; Baker, D. A.; Soderstrom, C.; Tkalcevic, G.; Rossi, A. M.; Miller, P. E.; Tengowski, M. W.; Wang, F.; Gualberto, A.; Beebe, J. S.; Moyer, J. D. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751, 871. Clin. Cancer Res., 2005, 11, 2063-73.
218. Cohen R. B.; Langer, C. J.; Simon, G. R.; Eisenberg, P. D.; Hainsworth, J. D.; Madajewicz, S.; Cosgriff, T. M.; Pierce, K.; Xu, H.; Liau, K.; Healey, D. A phase I/randomized phase II, noncomparative, multicenter, open label trial of CP-547, 632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC). Cancer Chemother. Pharmacol., 2007, 60, 81-9.
219. Karp, D. D.; Paz-Ares, L. G.; Novello, S.; Haluska, P.; Garland, L.; Cardenal, F.; Blakely, L. J.; Eisenberg, P. D.; Langer, C. J.; Blumenschein, G. Jr.; Johnson, F. M.; Green, S.; Gualberto, A. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751, 871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J. Clin. Oncol., 2009, 27, 2516-22.
220. Iwasa, T.; Okamoto, I.; Suzuki, M.; Hatashita, E.; Yamada, Y.; Fukuoka, M.; Ono, K.; Nakagawa, K. Inhibition of insulin-like growth factor 1 receptor by CP-751, 871 radiosensitizes non-small cell lung cancer cells. Clin. Cancer Res., 2009, 15, 5117-25.
221. Camirand, A.; Zakikhani, M.; Young, F.; Pollak, M. Inhibition of insulin-like growth factor-1 receptor signalling enhances growthinhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res., 2005, 7, R570-9.
222. Longo-Sorbello, G. S.; Bertino, J. R. Current understanding of methotrexate pharmacology and efficacy in acute leukemias. Use of newer antifolates in clinical trials. Haematologica, 2001, 86, 121-7.
223. Moore, B. S.; Eustáquio, A. S.; McGlinchey, R. P. Advances in and applications of proteasome inhibitors. Curr. Opin. Chem. Biol., 2008, 12, 434-40.
224. Tew, K. D. TLK-286: a novel glutathione S-transferase-activated prodrug. Expert Opin. Investig. Drugs, 2005, 14, 1047-54.
225. Cheng, K. L.; Bradley, T.; Budman, D. R. Novel microtubuletargeting agents - the epothilones. Biologics, 2008, 2, 789-811.
226. Longo-Sorbello, G. S.; Chen, B.; Budak-Alpdogan, T.; Bertino, J. R. Role of pemetrexed in non-small cell lung cancer. Cancer Invest., 2007, 25, 59-66.
227. Schultz, R. M.; Patel, V. F.; Worzalla, J. F.; Shih, C Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res., 1999, 19, 437-43.
228. Chen, V. J.; Bewley, J. R.; Andis, S. L.; Schultz, R. M.; Iversen, P. W.; Shih, C.; Mendelsohn, L. G.; Seitz, D. E.; Tonkinson, J. L. Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Br. J. Cancer, 1998, 78, 27-34.
229. Teicher, B. A.; Chen, V.; Shih, C.; Menon, K.; Forler, P. A.; Phares, V. G.; Amsrud, T. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin. Cancer Res., 2000, 6, 1016-23.
230. Rinaldi, D. A.; Kuhn, J. G.; Burris, H. A.; Dorr, F. A.; Rodriguez, G.; Eckhardt, S. G.; Jones, S.; Woodworth, J. R.; Baker, S.; Langley, C.; Mascorro, D.; Abrahams, T.; Von Hoff, D. D. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother. Pharmacol., 1999, 44, 372-80.
231. Hanna, N.; Shepherd, F. A.; Fossella, F. V.; Pereira, J. R.; De Marinis, F.; von Pawel, J.; Gatzemeier, U.; Tsao, T. C.; Pless, M.; Muller, T.; Lim, H. L.; Desch, C.; Szondy, K.; Gervais, R.; Shaharyar; Manegold, C.; Paul, S.; Paoletti, P.; Einhorn, L.; Bunn, P. A. Jr. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol., 2004, 22, 1589-97.
232. Ohe, Y.; Ichinose, Y.; Nakagawa, K.; Tamura, T.; Kubota, K.; Yamamoto, N.; Adachi, S.; Nambu, Y.; Fujimoto, T.; Nishiwaki, Y.; Saijo, N.; Fukuoka, M. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin. Cancer Res., 2008, 14, 4206-12.
233. Cullen, M. H.; Zatloukal, P.; Sörenson, S.; Novello, S.; Fischer, J. R.; Joy, A. A.; Zereu, M.; Peterson, P.; Visseren-Grul, C. M.; Iscoe, N. A randomized phase III trial comparing standard and highdose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Ann Oncol., 2008, 19, 939-45.
234. Smit, E. F.; Burgers, S. A.; Biesma, B.; Smit, H. J.; Eppinga, P.; Dingemans, A. M.; Joerger, M.; Schellens, J. H.; Vincent, A.; van Zandwijk, N.; Groen, H. J. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J. Clin. Oncol., 2009, 27, 2038-45.
235. Zhang, G. Z.; Jiao, S. C.; Meng, Z. T. Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients. J. Exp. Clin. Cancer Res., 2010, 29, 38.
236. de Boer, R.; Humblet, Y.; Wolf, J.; Nogová, L.; Ruffert, K.; Milenkova, T.; Smith, R.; Godwood, A.; Vansteenkiste, J. An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer. Ann. Oncol., 2009, 20, 486-91.
237. Scagliotti, G. V.; Parikh, P.; von Pawel, J.; Biesma, B.; Vansteenkiste, J.; Manegold, C.; Serwatowski, P.; Gatzemeier, U.; Digumarti, R.; Zukin, M.; Lee, J. S.; Mellemgaard, A.; Park, K.; Patil, S.; Rolski, J.; Goksel, T.; de Marinis, F.; Simms, L.; Sugarman, K. P.; Gandara, D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol., 2008, 26, 3543-51.
238. Scagliotti, G. V.; Park, K.; Patil, S.; Rolski, J.; Goksel, T.; Martins, R.; Gans, S. J.; Visseren-Grul, C.; Peterson, P. Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study. Eur. J. Cancer., 2009, 45, 2298-303.
239. Grønberg, B. H.; Bremnes, R. M.; Fløtten, O.; Amundsen, T.; Brunsvig, P. F.; Hjelde, H. H.; Kaasa, S.; von Plessen, C.; Stornes, F.; Tollåli, T.; Wammer, F.; Aasebø, U.; Sundstrøm, S. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as firstline chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol., 2009, 27, 3217-24.
240. Malhotra, B.; Evans, T.; Weiss, J.; Eaby, B.; Stonehouse-Lee, S.; Sherry, V.; Langer, C. J. Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience. Clin. Lung Cancer, 2010, 11, 192-7.
241. Vokes, E. E.; Senan, S.; Treat, J. A.; Iscoe, N. A. PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. Clin. Lung Cancer, 2009, 10, 193-8.
242. Peterson, P.; Park, K.; Fossella, F.; Gatzemeier, U.; John, W.; Scagliotti, G. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): P2-328. J. Thor. Onc., 2007, 2, S851.
243. Ling, Y. H.; Liebes, L.; Jiang, J. D.; Holland, J. F.; Elliott, P. J.; Adams, J.; Muggia, F. M.; Perez-Soler, R. Mechanisms of proteasome inhibitor PS-341-induced G (2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin. Cancer Res., 2003, 9, 1145-54.
244. Aghajanian, C.; Soignet, S.; Dizon, D. S.; Pien, C. S.; Adams, J.; Elliott, P. J.; Sabbatini, P.; Miller, V.; Hensley, M. L.; Pezzulli, S.; Canales, C.; Daud, A.; Spriggs, D. R. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res., 2002, 8, 2505-11.
245. Fanucchi, M. P.; Fossella, F. V.; Belt, R.; Natale, R.; Fidias, P.; Carbone, D. P.; Govindan, R.; Raez, L. E.; Robert, F.; Ribeiro, M.; Akerley, W.; Kelly, K.; Limentani, S. A.; Crawford, J.; Reimers, H. J.; Axelrod, R.; Kashala, O.; Sheng, S.; Schiller, J. H. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J. Clin. Oncol., 2006, 24, 5025-33.
246. Davies, A. M.; Chansky, K.; Lara, P. N. Jr.; Gumerlock, P. H.; Crowley, J.; Albain, K. S.; Vogel, S. J.; Gandara, D. R.; Southwest Oncology Group. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J. Thorac. Oncol., 2009, 4, 87-92.
247. Scagliotti, G. V.; Germonpré, P.; Bosquée, L.; Vansteenkiste, J.; Gervais, R.; Planchard, D.; Reck, M.; De Marinis, F.; Lee, J. S.; Park, K.; Biesma, B.; Gans, S.; Ramlau, R.; Szczesna, A.; Makhson, A.; Manikhas, G.; Morgan, B.; Zhu, Y.; Chan, K. C.; von Pawel, J. A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer, 2010, 68, 420-6.
248. Dudek, A. Z.; Lesniewski-Kmak, K.; Shehadeh, N. J.; Pandey, O. N.; Franklin, M.; Kratzke, R. A.; Greeno, E. W.; Kumar, P. Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Br. J. Cancer, 2009, 100, 1379-84
249. Lynch, T. J.; Fenton, D.; Hirsh, V.; Bodkin, D.; Middleman, E. L.; Chiappori, A.; Halmos, B.; Favis, R.; Liu, H.; Trepicchio, W. L.; Eton, O.; Shepherd, F. A. A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J. Thorac. Oncol., 2009, 4, 1002-9.
250. Li, T.; Ho, L.; Piperdi, B.; Elrafei, T.; Camacho, F. J.; Rigas, J. R.; Perez-Soler, R.; Gucalp, R. Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade ((R))) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC). Lung Cancer, 2010, 68, 89-93.
251. Moorghen, M.; Cairns, J.; Forrester, L. M.; Hayes, J. D.; Hall, A.; Cattan, A. R.; Wolf, C. R.; Harris, A. L. Enhanced expression of glutathione S-transferases in colorectal carcinoma compared to nonneoplastic mucosa. Carcinogenesis, 1991, 12, 13-7.
252. Koomägi, R.; Stammler, G.; Manegold, C.; Mattern, J.; Volm, M. Expression of resistance-related proteins in tumoral and peritumoral tissues of patients with lung cancer. Cancer Lett., 1996, 110, 129-36
253. Ali-Osman, F.; Brunner, J. M.; Kutluk, T. M.; Hess, K Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas. Clin. Cancer Res., 1997, 3, 2253-61
254. Huang, J.; Tan, P. H.; Thiyagarajan, J.; Bay, B. H. Prognostic significance of glutathione S-transferase-pi in invasive breast cancer. Mod. Pathol., 2003, 16, 558-65.
255. Rosen, L. S.; Laxa, B.; Boulos, L.; Wiggins, L.; Keck, J. G.; Jameson, A. J.; Parra, R.; Patel, K.; Brown, G. L. Phase 1 study of TLK286 (Telcyta) administered weekly in advanced malignancies. Clin. Cancer Res., 2004, 10, 3689-98.
256. Morgan, A. S.; Sanderson, P. E.; Borch, R. F.; Tew, K. D.; Niitsu, Y.; Takayama, T.; Von Hoff, D. D.; Izbicka, E.; Mangold, G.; Paul, C.; Broberg, U.; Mannervik, B.; Henner, W. D.; Kauvar, L. M. Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase. Cancer Res., 1998, 58, 2568-75.
257. Sequist, L. V.; Fidias, P. M.; Temel, J. S.; Kolevska, T.; Rabin, M. S.; Boccia, R. V.; Burris, H. A.; Belt, R. J.; Huberman, M. S.; Melnyk, O.; Mills, G. M.; Englund, C. W.; Caldwell, D. C.; Keck, J. G.; Meng, L.; Jones, M.; Brown, G. L.; Edelman, M. J.; Lynch, T. J. Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer. J. Thorac. Oncol., 2009, 4, 1389-96
258. Bollag, D. M.; McQueney, P. A.; Zhu, J.; Hensens, O.; Koupal, L.; Liesch, J.; Goetz, M.; Lazarides, E.; Woods, C. M. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res., 1995, 55, 2325-33.
259. Edelman, M. J. Novel taxane formulations and microtubule-binding agents in non-small-cell lung cancer. Clin. Lung Cancer, 2009, 10, S30-4.
260. Goodin, S.; Kane, M. P.; Rubin, E. H. Epothilones: mechanism of action and biologic activity. J. Clin. Oncol., 2004, 22, 2015-25.
261. Zhuang, S. H.; Agrawal, M.; Edgerly, M.; Bakke, S.; Kotz, H.; Thambi, P.; Rutt, A.; Balis, F. M.; Bates, S.; Fojo, T. A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer, 2005, 103, 1932-8
262. Vansteenkiste, J.; Lara, P. N. Jr.; Le Chevalier, T.; Breton, J. L.; Bonomi, P.; Sandler, A. B.; Socinski, M. A.; Delbaldo, C.; McHenry, B.; Lebwohl, D.; Peck, R.; Edelman, M. J. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J. Clin. Oncol., 2007, 25, 3448-55.
263. O'Reilly, T.; McSheehy, P. M.; Wenger, F.; Hattenberger, M.; Muller, M.; Vaxelaire, J.; Altmann, K. H.; Wartmann, M. Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo. Prostate, 2005, 65, 231-40.
264. Rubin, E. H.; Rothermel, J.; Tesfaye, F.; Chen, T.; Hubert, M.; Ho, Y. Y.; Hsu, C. H.; Oza AM. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J. Clin. Oncol., 2005, 23, 9120-9.
265. Horn, L.; Pao, W. EML4-ALK: Honing In on a New Target in Non-Small-Cell Lung Cancer. J. Clin. Oncol., 2009, 27, 4232-4235.
266. Soda, M.; Choi, Y. L.; Enomoto, M.; Takada, S.; Yamashita, Y.; Ishikawa, S.; Fujiwara, S.; Watanabe, H.; Kurashina, K.; Hatanaka, H.; Bando, M.; Ohno, S.; Ishikawa, Y.; Aburatani, H.; Niki, T.; Sohara, Y.; Sugiyama, Y.; Mano, H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 2007, 448, 561-6.
267. Shaw, A. T.; Yeap, B. Y.; Mino-Kenudson, M.; Digumarthy, S. R.; Costa, D. B.; Heist, R. S.; Solomon, B.; Stubbs, H.; Admane, S.; McDermott, U.; Settleman, J.; Kobayashi, S.; Mark, E. J.; Rodig, S. J.; Chirieac, L. R.; Kwak, E. L.; Lynch, T. J.; Iafrate, A. J. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol., 2009, 27, 4247-53.
268. Takahashi, T.; Sonobe, M.; Kobayashi, M.; Yoshizawa, A.; Menju, T.; Nakayama, E.; Mino, N.; Iwakiri, S.; Sato, K.; Miyahara, R.; Okubo, K.; Manabe, T.; Date, H. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann. Surg. Oncol., 2010, 17, 889-97.
269. Koivunen, J. P.; Mermel, C.; Zejnullahu, K.; Murphy, C.; Lifshits, E.; Holmes, A. J.; Choi, H. G.; Kim, J.; Chiang, D.; Thomas, R.; Lee, J.; Richards, W. G.; Sugarbaker, D. J.; Ducko, C.; Lindeman, N.; Marcoux, J. P.; Engelman, J. A.; Gray, N. S.; Lee, C.; Meyerson, M.; Jänne, P. A. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res., 2008, 14, 4275-83.
270. Kwak, E. L.; Camidge, D. R.; Clark, J.; Shapiro, G. I.; Maki, R. G.; Ratain, M. J.; Solomon, B.; Bang, Y.; Ou, S.; Salgia, R. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J. Clin. Oncol., 2009, 27, abstr 3509.
271. Bang, Y.; Kwak, E. L.; Shaw, A. T.; Camidge, D. R.; Iafrate, A. J.; Maki, R. G.; Solomon, B. J.; Ou, S. I.; Salgia, R.; Clark, J. W. Clinical activity of the oral ALK inhibitor PF-02341066 in ALKpositive patients with non-small cell lung cancer (NSCLC). J. Clin. Oncol., 2010, 28, abstr 3.
272. Breathnach, O. S.; Freidlin, B.; Conley, B.; Green, M. R.; Johnson, D. H.; Gandara, D. R.; O'Connell, M.; Shepherd, F. A.; Johnson, B. E. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J. Clin. Oncol., 2001, 19, 1734-42.
273. Cohen, M. H.; Williams, G. A.; Sridhara, R.; Chen, G.; McGuinn, W. D. Jr.; Morse, D.; Abraham, S.; Rahman, A.; Liang, C.; Lostritto, R.; Baird, A.; Pazdur, R. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin. Cancer Res., 2004, 10, 1212-8.
274. Johnson, J. R.; Cohen, M.; Sridhara, R.; Chen, Y. F.; Williams, G. M.; Duan, J.; Gobburu, J.; Booth, B.; Benson, K.; Leighton, J.; Hsieh, L. S.; Chidambaram, N.; Zimmerman, P.; Pazdur, R. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin. Cancer Res., 2005, 11, 6414-21.
275. Cohen, M. H.; Gootenberg, J.; Keegan, P.; Pazdur, R. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist, 2007, 12, 713-8.
276. Cohen, M. H.; Justice, R.; Pazdur, R. Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer. Oncologist, 2009, 14, 930-5.